Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could ...

Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

In this week’s edition of InnovationRx, we look at the FDA's new rules on Covid-19 vaccines, Novartis’s acquisition strategy, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The partnership will also naturally put Novartis in a favourable position if it decides to launch a takeover for Spark Therapeutics – though the long-term attractiveness of the Philadelphia ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pan American Silver (NYSE:PAAS) will acquire all of the issued and outstanding common shares of MAG Silver (NYSE:MAG).

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal ...

In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 2,899 calls trading, 1.4x expected, and implied vol increasing almost 2 points to 61.27%. Jun-25 30 calls and Oct-25 40 calls are ...